Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Subcutaneous Gamunex in Primary Immunodeficiency
NCT00389324Phase 2Completed
- Sponsor
- Grifols
- Start
- Nov 2006
- Primary completion
- Aug 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of intravenous human immunoglobulin in primary immunodeficiency (PI), sponsored by Grifols. Primary endpoint: Geometric Least Square Means of Area Under the Curve for Plasma Total Immunoglobulin G. Started Nov 2006; status: completed.
02
Drugs
intravenous human immunoglobulin
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT00389324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389324.